First Tracks Biotherapeutics, INC. (TRAX) — SEC Filings
Latest SEC filings for First Tracks Biotherapeutics, INC.. Recent 4 filing on Apr 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trad
View First Tracks Biotherapeutics, INC. on SEC EDGAR
Overview
First Tracks Biotherapeutics, INC. (TRAX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 23, 2026: On April 23, 2026, First Tracks Biotherapeutics, Inc. filed a Form 4, indicating changes in beneficial ownership of securities. The filing pertains to the period of report ending April 21, 2026. The document details transactions related to the company's securities.
Sentiment Summary
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant filing sentiment for First Tracks Biotherapeutics, INC. is neutral.
Filing Type Overview
First Tracks Biotherapeutics, INC. (TRAX) has filed 4 3, 2 4 with the SEC between Apr 2026.
Recent Filings (6)
-
First Tracks Biotherapeutics Files Form 4
— 4 · Apr 23, 2026 Risk: low
On April 23, 2026, First Tracks Biotherapeutics, Inc. filed a Form 4, indicating changes in beneficial ownership of securities. The filing pertains to the perio -
First Tracks Biotherapeutics Files Initial Ownership Statement
— 3 · Apr 23, 2026 Risk: low
On April 23, 2026, First Tracks Biotherapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. The filing was made by Ajim Ta -
EcoR1 Capital Reports Ownership Change in First Tracks Bio
— 4 · Apr 22, 2026 Risk: low
On April 20, 2026, EcoR1 Capital, LLC reported a change in beneficial ownership of securities for First Tracks Biotherapeutics, Inc. The filing, dated April 22, -
EcoR1 Capital Files Initial Ownership for First Tracks Bio
— 3 · Apr 22, 2026 Risk: low
On April 22, 2026, EcoR1 Capital, LLC filed a Form 3, an initial statement of beneficial ownership, for First Tracks Biotherapeutics, Inc. The filing indicates -
First Tracks Biotherapeutics Files Initial Ownership Statement
— 3 · Apr 1, 2026 Risk: low
On April 1, 2026, First Tracks Biotherapeutics, Inc. filed a Form 3, an initial statement of beneficial ownership of securities. The filing was made by Daniel F - 3 Filing — 3 · Apr 1, 2026
Risk Profile
Risk Assessment: Of TRAX's 5 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Ajim Tamboli
- Daniel Faga
Top Tags
insider-filing (4) · ownership (3) · ownership-change (2) · biotech (2) · insider-ownership (1)
Key Numbers
- Issuer CIK: 0002091349 — Unique identifier for First Tracks Biotherapeutics, Inc.
- Accession Number: 0001673528-26-000009 — Unique identifier for this specific SEC filing.
- Filing Date: 2026-04-01 — Date the Form 3 was filed with the SEC.
Frequently Asked Questions
What are the latest SEC filings for First Tracks Biotherapeutics, INC. (TRAX)?
First Tracks Biotherapeutics, INC. has 6 recent SEC filings from Apr 2026, including 4 3, 2 4. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TRAX filings?
Across 6 filings, the sentiment breakdown is: 6 neutral. The dominant sentiment is neutral.
Where can I find First Tracks Biotherapeutics, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all First Tracks Biotherapeutics, INC. (TRAX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for First Tracks Biotherapeutics, INC.?
Financial highlights for First Tracks Biotherapeutics, INC. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for TRAX?
Investment thesis data for TRAX will be available once enriched filings are processed.
Who are the key executives at First Tracks Biotherapeutics, INC.?
Key executives identified across First Tracks Biotherapeutics, INC.'s filings include Ajim Tamboli, Daniel Faga.
What are the main risk factors for First Tracks Biotherapeutics, INC. stock?
Of TRAX's 5 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from First Tracks Biotherapeutics, INC.?
Forward guidance and predictions for First Tracks Biotherapeutics, INC. are extracted from SEC filings as they are enriched.